HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up. 1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes.
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said " This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.'
The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children. 2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment. 4
"Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.
A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research. 3
'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' said Dr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.'
For the abstracts presented at ARVO 2025, please visit https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-arvo-2025/
*MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CORRECTING and REPLACING Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification
SEATTLE--(BUSINESS WIRE)--Please replace the release dated June 10, 2025 with the following corrected version due to multiple revisions. The updated release reads: Vouched Developing Integration in Epic Toolbox Under Construction for Remote Identity Verification Integration Empowers Hospitals to Streamline Patient Onboarding, Enhance Compliance, and Improve Care Delivery with Seamless AI-Driven Identity Verification in Epic Vouched, the AI-powered identity verification platform trusted by leading healthcare systems, is now officially developing integration within Epic Toolbox Under Construction — bringing faster, safer patient onboarding, MyChart account creation and account recovery directly into Epic. This milestone enables hospitals and healthcare systems to seamlessly integrate VouchedRx, a customized identity verification solution for healthcare providers, powerful identity verification technology directly into their Epic electronic health record (EHR) systems—enhancing patient intake, compliance, and operational efficiency. As a trusted partner in healthcare, Vouched's AI-based platform automates and streamlines identity verification, reducing manual steps and administrative burdens. With its inclusion in Epic Toolbox Under Construction, healthcare providers will soon be able to slash patient intake times, minimize fraud risk, and speed access to care — while meeting the highest security and compliance standards. 'Being part of Epic Toolbox Under Construction is a strategic milestone in our mission to become an indispensable technology partner to hospitals and healthcare systems,' said Peter Horadan, CEO of Vouched. 'Our inclusion allows us to support healthcare organizations in modernizing how they verify patient identities—an essential step in reducing fraud, improving patient outcomes, and driving down costs.' Epic Toolbox Under Construction highlights products in specific categories that will become available once development is released by Epic and participating developers. The designation also signifies that the product adheres to Epic's recommended connection practices for a category, making it easier for health systems to adopt cutting-edge technologies without lengthy custom development cycles. By joining this ecosystem, Vouched furthers our commitment to empowering healthcare organizations to implement best-in-class ID verification natively within their clinical workflows. As digital transformation in healthcare accelerates, identity verification remains a critical first step in ensuring patient data integrity and delivering equitable, efficient care. With Vouched now part of Epic Toolbox Under Construction, providers will soon gain access to a seamless and scalable solution for verifying identities across diverse patient populations, including telehealth, urgent care, and in-person settings. Epic and MyChart are registered trademarks of Epic Systems Corporation. About Vouched Vouched is a leading AI-powered identity verification platform serving industries with high-stakes verification needs like healthcare, finance, and automotive. Trusted by enterprises around the world, Vouched verifies millions of identities annually with speed, accuracy, and compliance. To learn more, visit
Business Wire
5 hours ago
- Business Wire
Lives on the Line: Komen® Speaks Out Against Reconciliation Bill as Millions Stand to Lose Coverage
DALLAS--(BUSINESS WIRE)-- Susan G. Komen ®, the world's leading nonprofit breast cancer organization, is deeply troubled by passage of the One Big Beautiful Bill Act which implements damaging reforms to federal health insurance programs. The Congressional Budget Office estimates these changes, combined with the failure to renew health care tax credits, could cause nearly 17 million people to lose their insurance coverage, increasing the U.S. uninsured rate by 30%. As a direct result of the actions of Congress, many breast cancer patients and survivors will lose their health care - shut out by unaffordable costs or trapped in bureaucratic red tape. For breast cancer patients and survivors, insurance coverage through Medicaid and the Affordable Care Act (ACA) Marketplaces is not a luxury; it is a lifeline. In the U.S., more than 72 million people rely on Medicaid. In fact, 1 in 10 adults with a history of cancer utilize Medicaid for insurance coverage. Millions of others rely on plans offered through the ACA Marketplaces. This health coverage is essential to ensuring timely access to breast cancer screening, diagnosis and treatment — care that might otherwise be delayed until the disease is more advanced, outcomes are worse and is expensive to treat. "The One Big Beautiful Bill Act includes changes that raise serious concerns for the breast cancer community,' said Paula Schneider, Komen president and CEO. 'Access to affordable, timely health care is critical — not only for those newly diagnosed, but also for those living with and beyond breast cancer. Policies that make it harder to secure coverage or navigate the system risk delaying care when every day counts. We urge our leaders to do better for the breast cancer community who depend on timely, affordable care." The bill will implement harsh work reporting requirements that would restrict access to quality and affordable healthcare for millions of patients falling between the gaps. Even with exemptions for those with serious illnesses, it remains unclear whether breast cancer patients would be required to navigate through administrative red tape to demonstrate their qualification. These patients already face an incredible burden of navigating our health care system on top of their medical care. The last thing a person undergoing cancer treatment needs is more paperwork, deadlines, and red tape every six months. Additional policies included in the bill make several harmful changes to ACA Marketplace plans which erodes coverage for millions of Americans, including breast cancer patients and survivors. These damaging policies come at a time when access to care is at its most vulnerable. Proposals to eliminate funding for the National Breast and Cervical Cancer Early Detection Program —a vital state-federal partnership which aims to increase early detection among women with low-incomes — combined with Congress' failure thus far to renew important health care tax credits would leave countless with nowhere to turn. Now that the One Big Beautiful Bill Act has passed, Congress must prioritize renewing the health care tax credits that help millions access coverage and fight against proposals to implement draconian cuts to NBCCEDP that further erode public health infrastructure. Komen urges Congress to do better for the breast cancer community and will continue to pursue policies that reverse or mitigate the damage done to patients through this legislation. Susan G. Komen ® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit or call 1-877 GO KOMEN. Connect with us on social at
Business Wire
5 hours ago
- Business Wire
Bioscience Association Manitoba Applauds Government Action to Advance Bioscience Research and Clinical Trials in Manitoba
WINNIPEG, Manitoba--(BUSINESS WIRE)--Bioscience Association Manitoba (BAM) welcomes the Manitoba government's latest announcement to launch a Clinical Trials Office, and the implementation of the Research Manitoba led project, Research Improvements Through Harmonization in Manitoba (RITHIM), both designed to accelerate and improve health research in the province. 'For too long, the process of moving innovative research into real-world care has taken longer in Manitoba than in other jurisdictions,' said Andrea Ladouceur, President & CEO of BAM. 'Both the new Manitoba Clinical Trials Office and RITHIM are key pieces of the puzzle that will help connect research to our ecosystem and shorten timelines and enables research to get where it's needed, into the lives of Manitobans.' Manitoba has led with action on the top 2 recommendations from the Manitoba Clinical Trials Working Group. The first is to create a Clinical Trials office to champion connections between researcher and resources and the second is to create a timebound standardized processes. BAM was honoured to co-chair this Working Group over the past 10 months developing recommendations to improve how research is conducted in the province. The new Manitoba Clinical Trials Office, announced by Honourable Jamie Moses, Minister of Business, Mining, Trade, and Job Creation, will help champion Manitoba as a destination for world-class clinical research. RITHIM will also help shorten process timelines. Learn more at 'Clinical trials are essential to getting new, innovative medicines into our healthcare system,' noted Ladouceur. 'Canada uses only about 20 per cent of the innovative medicines available in other G7 countries. Manitoba can and should lead the way in changing that.' The bioscience sector contributes approximately 7 per cent of Manitoba's GDP, with medicine ranked as the province's top export. Manitoba is home to a growing hub of companies like Bausch Health, Pfizer, Cytophage Technologies, Emergent, Kane Biotech, and Dynacare, which are developing solutions that help patients return to healthier lives. 'Our members are leaders in how we heal, feed, and fuel the world,' said Ladouceur. 'But innovation only matters if it reaches people. Many patients can't wait for life-saving treatments. That's why we need to continuously improve how we move research from the lab into people's lives,' noted Andrea. With this announcement, BAM sees Manitoba taking a strong step forward toward a more coordinated, responsive, and globally competitive research environment. 'We're proud to support this important milestone,' added Ladouceur. 'Manitoba is the right place for research to thrive with strong values around inclusivity, a commitment to quality, and a collaborative mindset. We look forward to what comes next.' For more information about this announcement, visit Bioscience Association Manitoba (BAM) is a not-for-profit industry association that enables commercial success for bioscience companies in Manitoba by acting as a catalyst for innovation, leading with one unified voice for all bioscience advancement and growth, and supporting a future-focused workforce. Learn more about Bioscience Association Manitoba:
